While there was a reduction in the number of tumors >2mm diameter in M(IL4)+AOM/DSS treated mice, the general pattern was that systemic delivery of M(IL4)s had negligible impact on the outcome of CRC in this model system. The gene discussed is IL4; the disease is colorectal carcinoma.